WASHINGTON, DC – Attorney General Irvin B. Nathan announced today that the District of Columbia and 37 states have reached a $90 million settlement with GlaxoSmithKline LLC (GSK) to resolve allegations that the company unlawfully promoted its anti-diabetes drug Avandia. The District’s share of the settlement, based on population and other factors, is $1,167,257.
The District and 37 states allege in complaints filed today that GSK violated state consumer protection laws by misrepresenting Avandia’s cardiovascular risks and safety profile. As part of the settlement, filed as a Consent Judgment in DC Superior Court, GSK agreed to reform how it markets and promotes diabetes drugs. The Consent Judgment prohibits GSK from, among other things: making any false, misleading, or deceptive claims about any diabetes drug; making comparative safety claims not supported by substantial evidence or substantial clinical experience; presenting favorable information previously believed to be valid but rendered invalid by contrary and more credible recent information; or promoting investigational drugs; or misusing statistics or otherwise misrepresenting the nature, applicability, or significance of clinical trials.
Attorney General Nathan said: “GSK violated the District’s consumer protection law by failing to disclose fully what it knew about the risks of a widely prescribed diabetes drug. The settlement protects consumers from this deceptive practice and compels future compliance with District law.”
- Ted Gest (202) 727-6283